ArticleDiscover oncology2025
Anoikis in hepatocellular carcinoma: genetic alterations and immune microenvironment insights from single-cell and computational analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is characterized by high heterogeneity, and its molecular features and microenvironment complexity contribute to varied patient prognoses. Anoikis, a form of programmed cell death, is considered closely linked to the development and progression of liver cancer. This study aimed to analyze the cellular heterogeneity of HCC using single-cell sequencing and to construct an anoikis-related prognostic model for predicting patient outcomes.
methodsSingle-cell sequencing data of HCC patients were obtained from the GEO database. The AUCell algorithm was used to quantify anoikis gene activity across cell types. Cells were grouped based on enrichment scores. Cox regression and 101 machine learning algorithms were employed to identify prognostic genes and construct a risk model, which was validated using TCGA, ICGC, and GEO datasets. Key findings were validated using qPCR on clinical samples, and functional assays using shRNA-mediated knockdown of KPNA2 were conducted in Hep-3B cell lines to assess changes in proliferation and migration.
resultsSingle-cell analysis revealed the cellular heterogeneity of HCC, with particular enrichment of anoikis-related genes in fibroblasts, endothelial cells, and macrophages. The prognostic model, developed using 101 algorithms, demonstrated the highest performance. High-risk patients showed poor prognosis, and the ROC curve analysis showed high accuracy for model predictions. Genetic mutation analysis indicated significant gene amplifications and deletions in the high-risk group. PCR analysis of clinical samples confirmed the expression patterns of key gene KPNA2, and gene knockdown in cell experiments further validated its oncogentic role in HCC.
conclusionThis study highlights the anoikis-related cellular heterogeneity in HCC and constructs a machine learning-based prognostic model with high predictive value, enabling effective risk stratification for patients. It offers further support for the potential therapeutic application of the identified genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.